The Korean journal of internal medicine

  • 제32권6호
  • /
  • Pages.974-983
  • /
  • 2017
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus

  • Moon, Min Kyong (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Hur, Kyu Yeon (Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ko, Seung-Hyun (Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, the Catholic University of Korea) ;
  • Park, Seok-O (Department of Internal Medicine, Gwangmyeong Sungae Hospital) ;
  • Lee, Byung-Wan (Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Kim, Jin Hwa (Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine) ;
  • Rhee, Sang Youl (Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine) ;
  • Kim, Hyun Jin (Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Choi, Kyung Mook (Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine) ;
  • Kim, Nan-Hee (Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine) ;
  • Committee of Clinical Practice Guidelines of the Korean Diabetes Association (Korean Diabetes Association)
  • 투고 : 2017.09.28
  • 심사 : 2017.10.20
  • 발행 : 2017.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM). In combination therapy of oral hypoglycemic agents (OHAs), general recommendations were not changed from those of the 2015 KDA guidelines. The Committee on Clinical Practice Guidelines of the KDA has extensively reviewed and discussed the results of meta-analyses and systematic reviews of effectiveness and safety of OHAs and many clinical trials on Korean patients with T2DM for the update of guidelines. All OHAs were effective when added to metformin or metformin and sulfonylurea, although the effects of each agent on body weight and hypoglycemia were different. Therefore, selection of a second agent as a metformin add-on therapy or third agent as a metformin and sulfonylurea add-on therapy should be based on the patient's clinical characteristics and the efficacy, side effects, mechanism of action, risk of hypoglycemia, effect on body weight, patient preference, and combined comorbidity. In this review, we address the results of meta-analyses and systematic reviews, comparing the effectiveness and safety among OHAs. It will help to choose the appropriate drug for an individual patient with T2DM.

키워드

참고문헌

  1. Korean Diabetes Association. Diabetes Fact Sheet in Korea 2016 [Internet]. Seoul (KR): Korean Diabetes Association, c2011 [cited 2017 Oct 20]. Available from: http://www.diabetes.or.kr/pro/news/admin.php?category=A&code=admin&number=1428&mode=view.
  2. Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014;37:9-16. https://doi.org/10.2337/dc13-2112
  3. Ha KH, Kim DJ. Current status of managing diabetes mellitus in Korea. Korean J Intern Med 2016;31:845-850. https://doi.org/10.3904/kjim.2016.253
  4. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40(Suppl 1):S64-S74. https://doi.org/10.2337/dc17-S011
  5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2017 executive summary. Endocr Pract 2017;23:207-238. https://doi.org/10.4158/EP161682.CS
  6. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740-751. https://doi.org/10.7326/M15-2650
  7. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378-388. https://doi.org/10.1016/j.diabres.2015.05.025
  8. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313-324. https://doi.org/10.1001/jama.2016.9400
  9. Zhou JB, Bai L, Wang Y, Yang JK. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. Int J Clin Pract 2016;70:132-141. https://doi.org/10.1111/ijcp.12761
  10. Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin- based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis. Clin Invest Med 2016;39:E48-E62.
  11. Amate JM, Lopez-Cuadrado T, Almendro N, et al. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int J Clin Pract 2015;69:292-304. https://doi.org/10.1111/ijcp.12605
  12. Seong JM, Choi NK, Shin JY, et al. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS One 2015;10:e0124287. https://doi.org/10.1371/journal.pone.0124287
  13. Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One 2016;11:e0166125. https://doi.org/10.1371/journal.pone.0166125
  14. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-950. https://doi.org/10.1016/S0140-6736(13)60683-2
  15. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-2022. https://doi.org/10.2337/dc11-0606
  16. Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700. https://doi.org/10.1016/S2213-8587(14)70120-2
  17. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016;18:783-794. https://doi.org/10.1111/dom.12670
  18. Yoon KH, Nishimura R, Lee J, et al. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials. Diabetes Obes Metab 2016;18:1045-1049. https://doi.org/10.1111/dom.12699
  19. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-1659. https://doi.org/10.2337/dc13-2105
  20. Min KW, Ku BJ, Lee JH, et al. Addition of ipragliflozin to metformin treatment in Korean patients with type 2 diabetes mellitus: subgroup analysis of a phase 3 trial. Diabetes Metab J 2017;41:135-145. https://doi.org/10.4093/dmj.2017.41.2.135
  21. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-2592. https://doi.org/10.1007/s00125-013-3039-1
  22. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-1238. https://doi.org/10.2337/dc11-1926
  23. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376-383. https://doi.org/10.2337/dc14-1142
  24. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-393. https://doi.org/10.2337/dc14-2364
  25. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326. https://doi.org/10.1056/NEJMoa1307684
  26. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335. https://doi.org/10.1056/NEJMoa1305889
  27. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242. https://doi.org/10.1056/NEJMoa1501352
  28. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128. https://doi.org/10.1056/NEJMoa1504720
  29. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334. https://doi.org/10.1056/NEJMoa1515920
  30. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657. https://doi.org/10.1056/NEJMoa1611925
  31. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708. https://doi.org/10.1007/s00125-012-2827-3
  32. Hong AR, Lee J, Ku EJ, et al. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res Clin Pract 2015;109:141-148. https://doi.org/10.1016/j.diabres.2015.04.019
  33. Jin SM, Park SW, Yoon KH, et al. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double- blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab 2015;17:511-515. https://doi.org/10.1111/dom.12429
  34. Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 2015;17:309-312. https://doi.org/10.1111/dom.12424
  35. Kim JH, Kim SS, Baek HS, et al. Comparison of vildagliptin and pioglitazone in Korean patients with type 2 diabetes inadequately controlled with metformin. Diabetes Metab J 2016;40:230-239. https://doi.org/10.4093/dmj.2016.40.3.230
  36. Jin SM, Park CY, Cho YM, et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double- blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab 2015;17:599-602. https://doi.org/10.1111/dom.12435
  37. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-1289. https://doi.org/10.1016/S0140-6736(05)67528-9
  38. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443. https://doi.org/10.1056/NEJMoa066224
  39. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on ${\beta}$-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552-1560. https://doi.org/10.2337/db10-1392
  40. Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study. Ann Med 2016;48:224-234. https://doi.org/10.3109/07853890.2016.1157263
  41. Downes MJ, Bettington EK, Gunton JE, Turkstra E. Triple therapy in type 2 diabetes: a systematic review and network meta-analysis. PeerJ 2015;3:e1461. https://doi.org/10.7717/peerj.1461
  42. Lee CM, Woodward M, Colagiuri S. Triple therapy combinations for the treatment of type 2 diabetes: a network meta-analysis. Diabetes Res Clin Pract 2016;116:149-158. https://doi.org/10.1016/j.diabres.2016.04.037
  43. Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. Curr Med Res Opin 2016;32:807-816. https://doi.org/10.1185/03007995.2015.1135110
  44. Mearns ES, Saulsberry WJ, White CM, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med 2015;32:1530-1540. https://doi.org/10.1111/dme.12837
  45. Ahn CH, Han KA, Yu JM, et al. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study). Diabetes Obes Metab 2017;19:635-643. https://doi.org/10.1111/dom.12866

피인용 문헌

  1. New anti-diabetic agents vol.60, pp.12, 2017, https://doi.org/10.5124/jkma.2017.60.12.992
  2. Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes vol.20, pp.5, 2017, https://doi.org/10.3390/ijms20051228
  3. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus vol.75, pp.12, 2019, https://doi.org/10.1007/s00228-019-02751-9
  4. SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients vol.13, pp.None, 2017, https://doi.org/10.2147/dmso.s193528
  5. Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study vol.44, pp.None, 2020, https://doi.org/10.4093/dmj.2020.0107
  6. Development and Validation of Rapid RP-HPLC and Green Second-Derivative UV Spectroscopic Methods for Simultaneous Quantification of Metformin and Remogliflozin in Formulation Using Experimental Design vol.7, pp.4, 2017, https://doi.org/10.3390/separations7040059
  7. Natural Compounds from Hatikana Extract Potentiate Antidiabetic Actions as Displayed by In Vivo Assays and Verified by Network Pharmacological Tools vol.2021, pp.None, 2017, https://doi.org/10.1155/2021/6978450
  8. Increasing Individual Target Glucose Levels to Prevent Hypoglycemia in Patients with Diabetes vol.42, pp.4, 2017, https://doi.org/10.4082/kjfm.19.0161
  9. Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment in vol.23, pp.8, 2017, https://doi.org/10.1111/dom.14400
  10. Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study vol.21, pp.1, 2017, https://doi.org/10.1186/s12890-021-01505-7
  11. Turmeric extract alleviates endocrine-metabolic disturbances in letrozole-induced PCOS by increasing adiponectin circulation: A comparison with Metformin vol.13, pp.None, 2017, https://doi.org/10.1016/j.metop.2021.100160